You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Details for New Drug Application (NDA): 202329


✉ Email this page to a colleague

« Back to Dashboard


NDA 202329 describes LANTHANUM CARBONATE, which is a drug marketed by Alkem Labs Ltd, Barr, Invagen Pharms, and Natco Pharma Ltd, and is included in four NDAs. It is available from five suppliers. Additional details are available on the LANTHANUM CARBONATE profile page.

The generic ingredient in LANTHANUM CARBONATE is lanthanum carbonate. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.
Summary for 202329
Tradename:LANTHANUM CARBONATE
Applicant:Alkem Labs Ltd
Ingredient:lanthanum carbonate
Patents:0
Pharmacology for NDA: 202329
Mechanism of ActionPhosphate Chelating Activity
Suppliers and Packaging for NDA: 202329
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 202329 ANDA Ascend Laboratories, LLC 67877-256 67877-256-90 2 BOTTLE in 1 CARTON (67877-256-90) / 45 TABLET, CHEWABLE in 1 BOTTLE (67877-256-45)
LANTHANUM CARBONATE lanthanum carbonate TABLET, CHEWABLE;ORAL 202329 ANDA Ascend Laboratories, LLC 67877-257 67877-257-90 6 BOTTLE in 1 CARTON (67877-257-90) / 15 TABLET, CHEWABLE in 1 BOTTLE (67877-257-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrengthEQ 500MG BASE
Approval Date:Mar 13, 2025TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrengthEQ 750MG BASE
Approval Date:Mar 13, 2025TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrengthEQ 1GM BASE
Approval Date:Mar 13, 2025TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links